IMPERIAL trial shows Eluvia outperforms Zilver PTX at one year


Andrew Holden (Auckland, News Zealand) interviews Stefan Mueller-Huelsbeck (Flensburg, Germany) to distil the key findings of the IMPERIAL trial one-year data that were presented for the very first time at CIRSE 2018 in Lisbon.

In the randomised controlled trial, Eluvia, which utilises a drug-polymer combination to offer sustained release of the drug paclitaxel, showed higher rates of primary patency at 12 months. Patients in the Eluvia arm of the study also experienced higher rates of freedom from target lesion revascularisation when compared to those treated with Zilver PTX.


Please enter your comment!
Please enter your name here